Evidence map›Paper›PMID 38142283›Full record

ArticlePalliative medicine2024

Reduction in potentially inappropriate end-of-life hospital care for cancer patients during the COVID-19 pandemic: A retrospective population-based study.

Ellis Slotman, Heidi P Fransen, Hanneke Wm van Laarhoven, Marieke Hj van den Beuken-van Everdingen, Vivianne Cg Tjan-Heijnen, Auke Mt Huijben, Agnes Jager, Lia van Zuylen, Evelien Jm Kuip, Yvette M van der Linden and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Palliative medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Ellis SlotmanDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.ORCID 0000-0001-6018-660X
Heidi P FransenDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
Hanneke Wm van LaarhovenDepartment of Medical Oncology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-3546-9709
Marieke Hj van den Beuken-van EverdingenCentre of Expertise for Palliative Care, Maastricht University Medical Centre, Maastricht, The Netherlands.ORCID 0000-0002-2446-2862
Vivianne Cg Tjan-HeijnenDepartment of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.
Auke Mt HuijbenDepartment of Internal Medicine, Maasstad Hospital, Rotterdam, The Netherlands.
Agnes JagerDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Lia van ZuylenDepartment of Medical Oncology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.
Evelien Jm KuipDepartment of Medical Oncology and Department of Anesthesiology, Pain and Palliative Care, Radboud Medical Center, Nijmegen, The Netherlands.
Yvette M van der LindenCentre of Expertise in Palliative Care, Leiden University Medical Centre, Leiden, The Netherlands.
Natasja Jh RaijmakersDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.ORCID 0000-0002-3000-2520
Sabine SieslingDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
Netherlands Comprehensive Cancer Organisation · NLAmsterdam University Medical Centers · NLMaastricht University Medical Centre · NLErasmus MC · NLLeiden University · NLMaasstad Ziekenhuis · NLRadboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic impacted cancer diagnosis and treatment. However, little is known about end-of-life cancer care during the pandemic.

aimTo investigate potentially inappropriate end-of-life hospital care for cancer patients before and during the COVID-19 pandemic.

designRetrospective population-based cohort study using data from the Netherlands Cancer Registry and the Dutch National Hospital Care Registration. Potentially inappropriate care in the last month of life (chemotherapy administration, >1 emergency room contact, >1 hospitalization, hospitalization >14 days, intensive care unit admission or hospital death) was compared between four COVID-19 periods and corresponding periods in 2018/2019.

participantsA total of 112,919 cancer patients (⩾18 years) who died between January 2018 and May 2021 were included.

resultsFewer patients received potentially inappropriate end-of-life care during the COVID-19 pandemic compared to previous years, especially during the first COVID-19 peak (22.4% vs 26.0%). Regression analysis showed lower odds of potentially inappropriate end-of-life care during all COVID-19 periods (between OR 0.81; 95% CI 0.74-0.88 and OR 0.92; 95% CI 0.87-0.97) after adjustment for age, sex and cancer type. For the individual indicators, fewer patients experienced multiple or long hospitalizations, intensive care unit admission or hospital death during the pandemic.

conclusionsCancer patients received less potentially inappropriate end-of-life care during the COVID-19 pandemic. Because several factors may have contributed, it is unclear whether this reflects better quality care. However, these findings raise important questions about what pandemic-induced changes in care practices can help provide appropriate end-of-life care for future patients in the context of increasing patient numbers and limited resources.

Indexed as

COVID-19NeoplasmsTerminal CareCohort StudiesDeathHospitalizationHospitalsHumansPalliative CarePandemicsRetrospective Studiescohort studiesCOVID-19neoplasmspalliative careterminal care

Identifiers

PMID38142283
PMCPMC10798006
OpenAlexW4390167857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.